Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Drug Induced Liver Disease
How do you counsel patients on the use and risks of alternative medications and supplements given how prevalent and easily accessible they are to the average person and their risk of liver injury?
Related Questions
When do you pursue liver biopsy for assessment of DILI?
How would you approach the management of drug-induced autoimmune hepatitis compared to non-drug-induced autoimmune hepatitis?
What is your endoscopic approach to the management of refractory GAVE in persistently anemic patients?
What is your strategy to manage the complication of long-term immunosuppression in liver transplant recipients, specifically renal dysfunction and onset of cardiometabolic comorbidities?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
What role is there for use of ELF in patients with active alcohol use disorder for which Fibroscan is not able to give a reliable assessment of fibrosis due to ongoing active alcohol use?
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
